他克莫司与霉酚酸酯持续诱导维持治疗狼疮性肾炎的96周前瞻性研究
结果显示两组第96周持续肾脏缓解率(SRR)无显著差异(58.5% vs 69.2%),完全肾脏缓解率(CRR)亦无显著差异(55.4% vs 63.1%)。总体不良事件发生率两组均为80.0%,但安全性谱不同:TAC组急性肾损伤和震颤更常见,MMF组白细胞减少更常见,且MMF组治疗相关严重不良事件和导致严重不良事件的感染显著更频繁。
要点
- TAC+GC与MMF+GC在96周SRR和CRR上无显著差异。
- 两组总体不良事件率均为80.0%,但安全性谱不同。
- MMF组治疗相关SAE和感染导致SAE更频繁,3例死亡均在该组。
核心结论
- TAC联合GC与MMF联合GC作为狼疮性肾炎持续诱导维持治疗,96周疗效无差异但安全性谱不同。
主要发现
- 第96周SRR在TAC组为58.5%,MMF组为69.2%,无显著差异。
- 第96周CRR在TAC组为55.4%,MMF组为63.1%,无显著差异。
- 第48周SRR在TAC组为63.1%,MMF组为66.2%。
- 总体不良事件发生率两组均为80.0%。
- TAC组急性肾损伤和震颤更常见,MMF组白细胞减少更常见;3例死亡均发生在MMF组。
关键数值与推荐
- TAC目标谷浓度为6-8 ng/mL。
- MMF剂量为1g每日两次。
- GC方案为静脉甲泼尼龙3天后口服泼尼松龙。
- 主要终点SRR定义为蛋白尿减少超过50%、eGFR不低于60 mL/min per 1.73m²,且无疾病复发或挽救治疗。
临床怎么用
- 对于III/IV型(伴或不伴V型)狼疮性肾炎,TAC+GC可作为MMF+GC的替代持续诱导维持方案,但需注意急性肾损伤和震颤风险。
- 使用MMF+GC时需警惕白细胞减少、治疗相关严重不良事件及感染导致严重不良事件的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We conducted a prospective Asian multicenter randomized controlled trial to evaluate the efficacy and safety of tacrolimus (TAC) and glucocorticoid (GC), against standard-of-care mycophenolate (MMF) and GC, as continuous induction-maintenance therapy for active lupus nephritis (LN) (ClinicalTrials.gov ID: NCT02630628). METHODS: One Hundred thirty biopsy-proven patients with Class III/IV without or with Class V LN were randomized to receive GC (intravenous methylprednisolone for three days then oral prednisolone) with either TAC (target trough level 6 - 8ng/mL) or MMF (1g twice a day) for 96 weeks. Primary endpoint was Sustained Renal Response (SRR) at week 96, defined as proteinuria reduction over 50% and estimated glomerular filtration rate no less than 60mL/min per 1.73m2, and no disease flare or rescue therapies. Secondary endpoints included rates of Complete Renal Remission (CRR) and Partial Renal Remission (PRR) at week 96, SRR at week 48, and adverse events (AE). RESULTS: TAC and MMF groups (65 patients each) showed no significant difference in the rates of SRR (58.5% vs 69.2% respectively) and CRR (55.4% vs 63.1% respectively) at week 96. SRR rates for TAC and MMF groups were 63.1% vs 66.2% at week 48, respectively. Overall, AE rates did not differ between TAC and MMF groups (80.0% in both). Acute kidney injury and tremors were more frequent in TAC group, while leucopoenia was more frequent in MMF group. Three deaths occurred, all in the MMF group. Treatment-related serious adverse events (SAE) and infection resulting in SAE were significantly more frequent in the MMF group. CONCLUSIONS: Dual immunosuppressive regimen with TAC and GC showed no difference in efficacy but different safety profile compared with MMF and GC over 96 weeks, when used as continuous induction-maintenance treatment for LN. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT02630628.
引用
- Yap DYH, Navarra SV, Ni Z, et al. Prospective 96-week study to evaluate efficacy and safety of tacrolimus and glucocorticoid against mycophenolate and glucocorticoid as continuous induction-maintenance treatment for Class III/IV without or with Class V lupus nephritis. Kidney Int. 2026. PMID: 42805336. doi:10.1016/j.kint.2026.08.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。